Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Adaptimmune Therapeutics plc. (5/10/17). "Press Release: Adaptimmune Reports First Quarter 2017 Financial Results". Philadeliphia, PA & Oxford.

Organisations Organisation Adaptimmune Therapeutics plc (Nasdaq: ADAP)
  Group Adaptimmune (Group)
  Organisation 2 Matrix Capital Management Company L.P.
Products Product AFP SPEAR™ T-cell therapy
  Product 2 NY-ESO SPEAR® T-cell therapy
Index term Index term Adaptimmune–Matrix Capital Management: investment, 201704 direct offering $42m of 7m ADSs at $6/ADS
Persons Person Noble, James (Adaptimmune CEO before MediGene 200609–200809 before Avidex)
  Person 2 Tayton-Martin, Helen (Adaptimmune 201703– CBO before COO + Co-Founder before Avidex/Medigene)

Record changed: 2017-05-28


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Adaptimmune (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px

» top